PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   343 Trials   12261 News 


«12...178179180181182183184185186187188...229230»
  • ||||||||||  dactolisib (RTB101) / resTORbio
    Journal:  The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines. (Pubmed Central) -  Mar 2, 2020   
    Understanding the molecular underpinnings of stem signatures in cancer will allow refinements to therapeutic strategies. Targeting FOXO factors to reduce stem cell characteristics in concert with PI3K inhibition may prove therapeutically efficacious.
  • ||||||||||  cisplatin / Generic mfg.
    Journal, IO Biomarker:  Ghrelin inhibits cisplatin-induced MDA-MB-231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling. (Pubmed Central) -  Mar 1, 2020   
    The effects of ghrelin on the cisplatin-induced apoptosis and PI3K/Akt/mTOR signaling were reversed by the growth hormone secretagogue receptor small interfering RNA. The present study suggests that ghrelin may serve as a novel target for cisplatin resistance and a potential indicator of cisplatin sensitivity in breast cancer treatment.
  • ||||||||||  Preclinical, Journal, IO Biomarker:  Hyperhomocysteinemia inhibits tibial fracture healing in rats through PI3K/AKT signaling pathway. (Pubmed Central) -  Mar 1, 2020   
    Compared with tibial fracture group, hHcys + fracture group had a higher level of plasma Hcy, lower ultimate bending strength and torque, lower relative protein expressions of PI3K and p-AKT, higher mRNA levels of Bax and caspase-3, a higher apoptosis rate and a higher expression of TNF-α. hHcys blocks the downstream apoptotic signal transduction, promotes apoptosis and inflammatory response, and affects fracture healing through affecting the PI3K/AKT signaling pathway.
  • ||||||||||  Journal, Cancer stem cells:  HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling. (Pubmed Central) -  Mar 1, 2020   
    FOXO6 knockdown can inhibit glycolysis of HCC cells and reduce their resistance to chemotherapy by inhibiting the PI3K/Akt signaling pathway, which may be a new target for the treatment of HCC. Down-regulation of HIF-2α expression can inhibit the stemness of human breast cancer MDA-MB-231 cells and promote apoptosis, and its mechanism may be related to the CD44/phosphoinosmde-3-kinase/AKT/mTOR signaling pathway.
  • ||||||||||  quercetin (LY294002) / Eli Lilly, dactolisib (RTB101) / resTORbio
    Journal:  PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma. (Pubmed Central) -  Mar 1, 2020   
    Down-regulation of HIF-2α expression can inhibit the stemness of human breast cancer MDA-MB-231 cells and promote apoptosis, and its mechanism may be related to the CD44/phosphoinosmde-3-kinase/AKT/mTOR signaling pathway. This study demonstrates that PI3K inhibitors ameliorate GC insensitivity in severe asthma by restoring HDAC2 activity and inhibiting the phosphorylation of nuclear signaling transcription factors.
  • ||||||||||  Journal:  Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry. (Pubmed Central) -  Feb 29, 2020   
    Unexpectedly, Erk, and not PI3K/Akt or Ral was activated by Ras at mid-G1, albeit PI3K/Akt signalling was a necessary companion of Ras/Erk for sustaining cyclin-D levels and G1/S transition. Our findings chart mitogenic signaling by endogenous Ras during G1 and identify limited effector engagement restricted to Raf/MEK/Erk as a cogent distinction from oncogenic Ras signalling.
  • ||||||||||  buparlisib (BKM120) / Novartis, Adlai Nortye
    Journal:  Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. (Pubmed Central) -  Feb 29, 2020   
    In three MLS cell lines, PI3K activity was inhibited by RNAi and the small-molecule PI3K inhibitor BKM120 (buparlisib) in vitro An MLS cell line-based avian chorioallantoic membrane model was applied for in vivo confirmation...PI3K‑directed therapeutic interference showed that myxoid liposarcoma cell proliferation and viability significantly depended on PI3K-mediated signals in vitro and in vivo. Our preclinical study underlines the elementary role of PI3K/Akt signals in myxoid liposarcoma tumorigenesis and provides a molecularly based rationale for a PI3K‑targeted therapeutic approach which may be particularly effective in tumors carrying activating genetic alterations in PI3K/Akt signaling components.
  • ||||||||||  ETC159 / Experimental Therapeutics Centre, pictilisib (GDC-0941) / Roche
    Journal:  PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. (Pubmed Central) -  Feb 28, 2020   
    This was largely due to enhanced suppressive effects on both cell proliferation and glucose metabolism. These findings demonstrate that dual PORCN and PI3K/mTOR inhibition is a potential strategy for treating Wnt-driven pancreatic cancers.
  • ||||||||||  Journal:  CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway. (Pubmed Central) -  Feb 28, 2020   
    Furthermore, in vivo xenograft experiments demonstrated that cytosolic nonspecific dipeptidase 2 can promote the development and progression of ovarian cancer, increasing the expression of phosphorylated PI3K and AKT. Cytosolic nonspecific dipeptidase 2 promotes the occurrence and development of ovarian cancer through the PI3K/AKT signaling pathway.
  • ||||||||||  Aliqopa (copanlisib) / Bayer, Copiktra (duvelisib) / Verastem
    Biomarker, Journal:  Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. (Pubmed Central) -  Feb 28, 2020   
    Cytosolic nonspecific dipeptidase 2 promotes the occurrence and development of ovarian cancer through the PI3K/AKT signaling pathway. IL-6-induced STAT3 or STAT5 activation is a critical mechanism underlying PI3K inhibitor resistance in lymphoma, supporting the utility of IL-6 as an effective biomarker to predict therapeutic response to PI3K inhibitors.
  • ||||||||||  omipalisib (GSK2126458) / GSK, danusertib (PHA-739358) / Nerviano Medical Sciences
    Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma (The Westin Kierland Resort and Spa) -  Feb 27, 2020 - Abstract #MHNCS2020MHNCS_247;    
    P2
    To the best of our knowledge, this is the first study to identify Aurora kinases as a mechanism of resistance to PI3K inhibition in any cancer type. The finding that the combination of PI3K and Aurora kinase inhibition led to synergy in both NOTCH1 mutant and wt HNSCC suggests that this combination will be broadly effective in HNSCC patients who may have heterogeneous tumors.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Review, Journal:  Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. (Pubmed Central) -  Feb 27, 2020   
    The use of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors palbociclib, ribociclib and abemaciclib of the mammalian target of rapamycin (mTOR) inhibitor everolimus and of the phosphoinositide 3 kinase (PI3K) inhibitor taselisib together with endocrine therapy (ET) has become a standard in advanced breast cancer, showing clinical effectiveness and significantly prolonging median progression-free survival compared to ET only...In this context, the use of genomic-transcriptomic tools (such as ONCOTYPE, PAM50) and the identification of novel biomarkers (ESR1, PI3Kca, PDGF-R) on tissue or with liquid biopsy could help to select patient prone to respond to endocrine-combined therapy and able to achieve pCR. With our review, we aimed at evaluating the current state of the art in the treatment of locally advanced breast cancer with NEO-HT.
  • ||||||||||  Rozlytrek (entrectinib) / Roche, paxalisib (GDC-0084) / Kazia, Verzenio (abemaciclib) / Eli Lilly
    [VIRTUAL] Alliance A071701: Genomically guided treatment trial in brain metastases. (Poster Board 64) -  Feb 27, 2020 - Abstract #ASCO2020ASCO_232;    
    P2
    This study represents a novel individualized therapeutic approach in brain metastases, a disease with a critical need for effective therapy. Research Funding: U.S. National Institutes of Health, Pharmaceutical/Biotech Company, U.S. National Institutes of Health
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    Journal:  AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. (Pubmed Central) -  Feb 26, 2020   
    Thus, AZD9291 was found to induce autophagy, decrease in EGFR levels, and show a strong inhibitory effect on NSCLC both in vitro and in vivo. Furthermore, the PI3K/Akt signaling pathway was found to play a critical role in AZD9291-induced cell death.
  • ||||||||||  quercetin (LY294002) / Eli Lilly, dactinomycin / Generic mfg.
    Journal:  Zinc induces iron uptake and DMT1 expression in Caco-2 cells via a PI3K/IRP2 dependent mechanism. (Pubmed Central) -  Feb 26, 2020   
    In agreement with these findings zinc treatment stabilized DMT1 mRNA levels in actinomycin-D treated cells. Based on these findings, we conclude that zinc-induced iron absorption involves elevation of DMT1 expression via stabilization of its mRNA, via a PI3K/IRP2-dependent mechanism.
  • ||||||||||  Journal:  Precision medicine: PI3K targeting in advanced breast cancer. (Pubmed Central) -  Feb 26, 2020   
    In conclusion, SW induced autophagy via pI3K/AKT/mTOR signaling pathway and revealed the role of autophagy in causing the SW toxicity characterized by the vacuolar degeneration. No abstract available